RCAN2 and metabolic dysfunction-associated steatotic liver disease: In the present study, we aimed to conduct the first study to evaluate serum RCAN2 levels in NAFLD patients and non-NAFLD subjects, and the association of serum RCAN2 with NAFLD risk.